About Timber Pharmaceuticals
Board of Directors
Michael Derby, MS, MBA
Michael is a successful biopharmaceutical entrepreneur, operating executive and investor. He has founded or co-founded multiple biopharmaceutical companies and has a passion for developing and commercializing innovative products that can make a major impact on the lives of patients globally.
John Koconis, MBA
CHIEF EXECUTIVE OFFICER
John has had a highly accomplished career as both a strategic and operational leader in the pharmaceutical sector with over 25 years of experience leading successful teams in global markets and launching multiple market-leading products. John brings a unique perspective through his experience in broad, specialty and rare/orphan dermatology development and commercialization.
CHIEF OPERATING OFFICER
Zach is a biopharmaceutical inventor, entrepreneur and executive. He is a Co-Founder of Timber and has served as the Company’s President since its inception. Zach is also a Partner at TardiMed Sciences, a life sciences company creation firm. At TardiMed, Zach has helped to form several life sciences companies that span multiple therapeutic areas and stages of development.
David Cohen, MD
Dr. Cohen is the Charles C. and Dorothea E. Harris Professor of Dermatology at New York University School of Medicine, where he also serves as Chief of Allergy and Contact Dermatitis, Vice Chairman of Clinical Affairs, and Director of Occupational and Environmental Dermatology. Dr. Cohen joined the NYU faculty in 1994 and his work has concentrated on cutaneous allergic and toxic reactions to exogenous and photo-reactive chemicals and the interaction of environmental stressors on the skin.
Lubor Gaal, PhD
Lubor Gaal, PhD is Senior Vice President and Head of Europe at Locust Walk, a global life science transaction firm with offices in Boston, San Francisco, Tokyo and Europe, where is leading and managing corporate and business development or financing transactions for many innovative European biotechnology and pharmaceutical companies across various therapeutic areas.
Gianluca Pirozzi, PhD
Dr. Pirozzi is Senior Vice President, Head of Clinical Development and Translational Sciences at Alexion Pharmaceuticals. Dr. Pirozzi joined Alexion in October 2019 and has nearly two decades of experience in drug development, previously serving various roles at Sanofi Genzyme, including Head of Development for Rare Diseases and Gene Therapy, and Global Project Head for Dupixent®.
Edward Sitar, CPA
Ed Sitar, CPA, Chair of our Audit Committee has extensive financial leadership in public Companies and has served as CFO in a variety of public companies including 9 Meters Biopharma (Nasdaq:NMTR), Cancer Genetics (Nasdaq:CGIX), Active Health Management (subsidiary of Aetna - Nasdaq AET), Vital Signs (Nasdaq:VITL) and MIM corporation (now BioScrip - Nasdaq:BIOS).